Mutation in the factor II gene
Material: Blood
Price of the study: 210 PLN
Waiting time: result after 21 working days
Booking:
Price of the study: 210 PLN
Waiting time: result after 21 working days
Booking:
- Check, the hours of operation of the collection center and where booking an appointment is required.
Preparation for the study
General
- The test material is blood.
- The patient does not need to be fasting.About 30 minutes before the test it is advisable to drink a glass of water.
Important
Samples brought from outside are not accepted for testing.
Description
The test is performed to assess the risk and/or causes of venous thromboembolism.
Prothrombin belongs to a group of plasma proteins that, as a result of damage to blood vessels, are subject to activation and are involved in the process of blood clotting. As a result of mutation 20210a in the prothrombin gene, there is an increased synthesis and accumulation of prothrombin in the blood, which raises the risk of thromboembolic diseases (venous and arterial thrombosis, myocardial infarction, stroke).The increased risk of blood vessel thrombosis also has important implications for pregnant women. Carrying a prothrombin gene mutation significantly increases the risk of spontaneous miscarriage in the first trimester of pregnancy and numerous pathologies of pregnancy in the third trimester, such as placental detachment and fetal stunting, among others.
It is estimated that the risk of thrombotic and embolic lesions in people with the 20210a mutation of the prothrombin gene increases 2-3 times, and in combination with a mutation of the factor V Leiden gene even 10-20 times. Other acquired prothrombotic factors:
pregnancy,
hormone replacement therapy,
oral contraception
or surgery further increase the risk of symptoms.
Testing for prothrombin gene mutation 20210a and factor V Leiden is ordered when the first incident of venous or arterial thrombosis occurred at a relatively young age (under 50), or in an unusual area of the body.
The test may also be ordered if the patient has a family history of recurrent thrombotic incidents.
The test is performed using a molecular biology technique
Prothrombin belongs to a group of plasma proteins that, as a result of damage to blood vessels, are subject to activation and are involved in the process of blood clotting. As a result of mutation 20210a in the prothrombin gene, there is an increased synthesis and accumulation of prothrombin in the blood, which raises the risk of thromboembolic diseases (venous and arterial thrombosis, myocardial infarction, stroke).The increased risk of blood vessel thrombosis also has important implications for pregnant women. Carrying a prothrombin gene mutation significantly increases the risk of spontaneous miscarriage in the first trimester of pregnancy and numerous pathologies of pregnancy in the third trimester, such as placental detachment and fetal stunting, among others.
It is estimated that the risk of thrombotic and embolic lesions in people with the 20210a mutation of the prothrombin gene increases 2-3 times, and in combination with a mutation of the factor V Leiden gene even 10-20 times. Other acquired prothrombotic factors:
pregnancy,
hormone replacement therapy,
oral contraception
or surgery further increase the risk of symptoms.
Testing for prothrombin gene mutation 20210a and factor V Leiden is ordered when the first incident of venous or arterial thrombosis occurred at a relatively young age (under 50), or in an unusual area of the body.
The test may also be ordered if the patient has a family history of recurrent thrombotic incidents.
The test is performed using a molecular biology technique
Development and preparation of material (applies to contractors only)
982
